ImageneBio (NASDAQ:IMA) Releases Quarterly Earnings Results

ImageneBio (NASDAQ:IMA) released its quarterly earnings results on Monday. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.08), FiscalAI reports.

ImageneBio Price Performance

ImageneBio stock traded up $0.03 during midday trading on Wednesday, reaching $3.84. The company’s stock had a trading volume of 2,507 shares, compared to its average volume of 114,869. The stock’s 50-day simple moving average is $4.48 and its 200-day simple moving average is $5.55. ImageneBio has a 52-week low of $3.60 and a 52-week high of $8.70. The stock has a market capitalization of $43.58 million, a P/E ratio of -0.84 and a beta of 0.83.

Institutional Investors Weigh In On ImageneBio

A number of large investors have recently modified their holdings of the business. Blue Owl Capital Holdings LP purchased a new position in shares of ImageneBio in the 2nd quarter valued at approximately $5,414,000. Cable Car Capital LP purchased a new stake in ImageneBio during the 2nd quarter worth approximately $4,611,000. Trails Edge Capital Partners LP purchased a new stake in ImageneBio during the 2nd quarter worth approximately $1,663,824. BML Capital Management LLC increased its stake in ImageneBio by 13.4% during the 1st quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock valued at $1,004,000 after purchasing an additional 23,704 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in ImageneBio during the 2nd quarter valued at approximately $797,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Wall Street Analyst Weigh In

IMA has been the subject of several recent analyst reports. HC Wainwright began coverage on shares of ImageneBio in a research note on Friday, August 21st. They set a “buy” rating and a $28.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research note on Friday, September 25th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $28.00.

ImageneBio Company Profile

ImageneBio, Inc. is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples. Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions. ImageneBio combines molecular analysis with computational tools to translate circulating biological information into insights for oncology research and clinical use.